A new drug with a novel mechanism of action against tuberculosis infection shows promise for treating multidrug-resistant tuberculosis (MDR-TB), according to interim results in an ongoing phase 2, randomized placebo-controlled trial conducted by an international team of researchers (Diacon AH et al. N Engl J Med. 2009;360:2397-2405).
The drug, TMC207, is a diarylquinoline that inhibits the enzyme adenosine triphosphate (ATP) synthase, disrupting the production of ATP, the molecule that serves as the energy currency of cells.
Stephenson J. Treating Multidrug-Resistant TB. JAMA. 2009;302(3):246. doi:10.1001/jama.2009.1015